Coagadex: Uses, Dosage & Side Effects
A plasma-derived human coagulation factor X concentrate for the treatment and prevention of bleeding in hereditary factor X deficiency
Coagadex is a plasma-derived human coagulation factor X concentrate specifically developed for the treatment of hereditary factor X deficiency, one of the rarest inherited bleeding disorders. It is the first and only factor X-specific replacement therapy approved by both the EMA and FDA. Coagadex is administered intravenously to treat and prevent bleeding episodes, and to provide hemostatic coverage during surgical procedures. Available as a powder for reconstitution, it requires a prescription and is typically managed by a specialist hematologist.
Quick Facts: Coagadex
Key Takeaways
- Coagadex is the first and only approved factor X-specific concentrate for treating hereditary factor X deficiency, one of the rarest inherited bleeding disorders affecting approximately 1 in 500,000 to 1 in 1,000,000 people.
- The medication is administered by intravenous injection and must be reconstituted from a powder using the supplied solvent and Mix2Vial transfer device; after preparation, it must be used within one hour.
- The maximum daily dose must not exceed 60 IU/kg in any age group; children under 12 years typically require higher doses per kilogram than adults or adolescents.
- Patients may develop inhibitory antibodies (inhibitors) against factor X during treatment, which can reduce the effectiveness of the medication; regular monitoring by a hematologist is essential.
- As a plasma-derived product, Coagadex undergoes rigorous viral inactivation steps, but a theoretical risk of pathogen transmission cannot be entirely eliminated; vaccination against hepatitis A and B may be recommended.
What Is Coagadex and What Is It Used For?
Coagadex is a highly purified concentrate of human coagulation factor X, a critical protein in the blood clotting cascade. It is manufactured from human plasma (the liquid component of blood) through a process that includes multiple steps to ensure purity and safety. Approved by the European Medicines Agency (EMA) in 2016 and the U.S. Food and Drug Administration (FDA) in 2015, Coagadex represents a significant therapeutic advance as the first and only factor X-specific replacement therapy available for clinical use.
Factor X occupies a central position in the coagulation cascade, serving as the convergence point of both the intrinsic and extrinsic pathways. When activated to factor Xa, it forms part of the prothrombinase complex together with factor Va, phospholipids, and calcium ions. This complex converts prothrombin (factor II) to thrombin, which in turn converts fibrinogen to fibrin, the protein mesh that forms the structural basis of a blood clot. Without adequate factor X levels, this cascade is disrupted and the body cannot form stable blood clots effectively.
Hereditary factor X deficiency (also known as Stuart-Prower factor deficiency) is an autosomal recessive bleeding disorder. It is one of the rarest coagulation factor deficiencies, with an estimated prevalence of approximately 1 in 500,000 to 1 in 1,000,000 in the general population. The condition results from mutations in the F10 gene located on chromosome 13, which lead to either reduced production (type I deficiency) or production of a dysfunctional factor X protein (type II deficiency). Clinical severity varies widely, ranging from mild bruising to life-threatening hemorrhages including intracranial bleeding.
Patients with severe factor X deficiency (factor X activity levels below 10% of normal) may experience spontaneous bleeding episodes including joint bleeds (hemarthrosis), muscle bleeds, gastrointestinal hemorrhage, and excessive bleeding following injury or surgery. Women with factor X deficiency frequently experience heavy menstrual bleeding (menorrhagia) and may face complications during pregnancy and childbirth. Before the availability of Coagadex, patients were treated with fresh frozen plasma (FFP) or prothrombin complex concentrates (PCCs), which carry higher risks of volume overload and thrombotic complications.
Coagadex is indicated for three primary clinical scenarios: on-demand treatment of acute bleeding episodes, perioperative management (before, during, and after surgical procedures), and routine prophylaxis to prevent recurrent bleeding in patients with a history of frequent hemorrhagic events. The specific dose and treatment regimen are determined by the treating hematologist based on the patient's baseline factor X level, body weight, clinical situation, and individual pharmacokinetic response.
What Should You Know Before Using Coagadex?
Contraindications
There is one absolute contraindication to using Coagadex: a known allergy (hypersensitivity) to human coagulation factor X or to any of the excipients in the formulation. These excipients include citric acid, disodium phosphate dihydrate, sodium chloride, sodium hydroxide, and sucrose. If you have previously experienced an allergic reaction to any plasma-derived coagulation factor product, discuss this with your doctor before starting treatment with Coagadex, as cross-reactivity may occur.
Warnings and Precautions
Rare cases of allergic reactions (hypersensitivity) have been reported with similar plasma-derived coagulation factor products. Signs may include skin rash, hives, tingling, hot flushes, nausea, vomiting, headache, cough, wheezing, chest tightness, chills, rapid heartbeat, dizziness, lethargy, restlessness, facial swelling, throat tightness, and discomfort at the injection site. In severe cases, this can progress to anaphylactic shock. If you experience any of these symptoms, stop the injection and contact your doctor immediately.
Several important warnings and precautions should be considered before and during treatment with Coagadex. Your treating physician and hematology team will monitor you closely, particularly at the start of treatment and around surgical procedures.
Inhibitor development: Some patients with factor X deficiency may develop inhibitory antibodies (inhibitors) against factor X during treatment. Inhibitors are immune system proteins that neutralize the administered factor X, rendering the treatment less effective or ineffective. If you notice that your bleeding does not stop or continues longer than expected after an injection, contact your healthcare provider immediately. Your doctor will perform regular laboratory tests to monitor for inhibitor development, especially before surgical procedures. Both before and after treatment, and particularly during your first treatments, your doctor will likely test your blood factor X levels to ensure the medication is working as expected.
If you are taking a direct factor Xa inhibitor (such as rivaroxaban, apixaban, or edoxaban), these medications may counteract the effect of Coagadex. Factor Xa inhibitors work by blocking the activity of activated factor X, which is the same protein that Coagadex is designed to provide. Tell your doctor about all medications you are taking.
Viral safety: Because Coagadex is manufactured from human plasma, special measures are taken during manufacturing to prevent the transmission of infectious agents to patients. These include careful screening of blood and plasma donors to exclude those who may carry infections, testing of donated plasma for signs of viruses and infections, and inclusion of manufacturing steps specifically designed to inactivate or remove viruses.
The measures taken are considered effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), as well as non-enveloped viruses such as hepatitis A virus (HAV) and parvovirus B19. Despite these extensive precautions, the risk of transmitting an infection cannot be entirely eliminated when medicines made from human blood or plasma are administered. This also applies to unknown or newly emerging viruses and other types of infections.
Each time you receive a dose of Coagadex, it is strongly recommended that the product name and batch number are recorded to maintain traceability. Your doctor may recommend vaccination against hepatitis A and hepatitis B if you regularly or repeatedly receive human plasma-derived factor X products.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using Coagadex. There is limited clinical experience with the use of Coagadex during pregnancy and breastfeeding. As with all medications during pregnancy, the decision to use Coagadex should be based on a careful assessment of the benefits versus the potential risks, made in consultation with your treating hematologist and obstetrician. Women with factor X deficiency face an increased risk of bleeding complications during pregnancy and delivery, so careful management by a specialized team is essential.
Use in Children and Adolescents
The warnings and precautions listed for adults also apply to children (aged 2 to 11 years) and adolescents (aged 12 to 18 years). Coagadex has been studied in pediatric patients, and the safety profile in children and adolescents is consistent with that observed in adults. However, children under 12 years of age typically require higher doses per kilogram of body weight to achieve adequate factor X levels compared to adults and adolescents.
Sodium Content
Coagadex contains up to 9.2 mg of sodium (the main component of table salt) per milliliter of reconstituted solution. This is equivalent to approximately 0.0046% of the WHO-recommended maximum daily sodium intake for adults. This should be taken into consideration by patients on a controlled sodium diet, although the amount is very small relative to daily intake.
Driving and Operating Machinery
Coagadex has no known effects on the ability to drive vehicles or operate machinery. There are no reported cases of impaired alertness, reaction time, or cognitive function associated with the use of this medication.
How Does Coagadex Interact with Other Drugs?
No formal drug-drug interaction studies have been conducted with Coagadex. However, based on the pharmacological mechanism of action and the clinical understanding of the coagulation cascade, several potential interactions should be considered. It is important to tell your doctor about all medications you are currently using, have recently used, or may plan to use, including over-the-counter medicines, herbal preparations, and dietary supplements.
Major Interactions
| Drug / Drug Class | Interaction | Clinical Significance |
|---|---|---|
| Direct Factor Xa Inhibitors (rivaroxaban, apixaban, edoxaban) | These anticoagulants work by specifically blocking factor Xa activity, directly counteracting the therapeutic effect of Coagadex | Concurrent use may render Coagadex ineffective; discuss alternatives with your hematologist |
| Warfarin and other vitamin K antagonists | Vitamin K antagonists reduce hepatic synthesis of vitamin K-dependent clotting factors, including factor X | May reduce the duration of effect of administered Coagadex; close monitoring of factor X levels required |
| Heparin (unfractionated and LMWH) | Heparin potentiates antithrombin III activity, which inhibits multiple coagulation factors including factor Xa | May partially reduce the hemostatic efficacy of Coagadex; use with caution and monitor closely |
Minor Interactions and Considerations
While no formal interactions have been documented, certain medications warrant mention due to their effects on hemostasis. Antiplatelet agents such as aspirin, clopidogrel, and ticagrelor affect platelet function and may theoretically increase bleeding risk in patients with factor X deficiency, even when receiving Coagadex replacement therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen can impair platelet function and irritate the gastrointestinal mucosa, potentially increasing the risk of gastrointestinal bleeding.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) may also affect platelet function by depleting serotonin in platelets. Certain herbal supplements, including ginkgo biloba, garlic extract, and fish oil, have antiplatelet or anticoagulant properties that may potentiate bleeding risk. Always inform your healthcare provider about all substances you are taking, including supplements and herbal remedies.
There are no known interactions between Coagadex and common medications such as paracetamol (acetaminophen), antibiotics, or antihypertensive drugs. However, because Coagadex is a specialized hematology product, all treatment decisions should be coordinated with your hematologist, especially when starting, stopping, or changing other medications.
What Is the Correct Dosage of Coagadex?
Treatment with Coagadex should be initiated and supervised by a physician experienced in the management of bleeding disorders. The dosage is individualized for each patient based on their baseline factor X activity level, body weight, and the clinical scenario (on-demand treatment, surgical coverage, or prophylaxis). Your doctor will typically describe your dose in terms of the number of full vials that provide the most appropriate dose for you.
Adults
On-Demand Treatment of Bleeding Episodes
Your doctor will determine how much Coagadex to administer based on your baseline factor X level and the severity of the bleeding episode. The dose should be sufficient to achieve and maintain adequate hemostasis. Treatment should begin at the first sign of bleeding and may be repeated as needed to control the hemorrhage. Each individual bleeding episode should be assessed based on its own severity.
Perioperative Management (Surgical Coverage)
Before surgery: The pre-operative dose should be sufficient to raise the plasma factor X level to between 70 and 90 IU/dL. The exact dose required depends on the patient's baseline factor X level and is calculated by the treating physician.
After surgery: During the initial days following surgery, plasma factor X concentrations will be monitored regularly. It is recommended that factor X levels be maintained above 50 IU/dL throughout the postoperative recovery period. The required dose will be calculated by your physician based on ongoing monitoring.
Routine Prophylaxis
Your doctor will determine whether routine prophylaxis is appropriate for you and what dose should be used. Prophylaxis may be recommended for patients who experience frequent spontaneous bleeding episodes, particularly joint and muscle bleeds, to prevent long-term complications such as arthropathy (joint damage).
Children and Adolescents
Coagadex can be used in children aged 2 years and older and in adolescents. Your doctor will recommend an appropriate dose based on the child's weight and factor X levels. Doses for children under 12 years are generally higher per kilogram of body weight than for adolescents and adults, reflecting the faster clearance of factor X in younger patients. Doses for adolescents (12 to 18 years) are the same as for adults.
| Age Group | Dose Considerations | Maximum Daily Dose |
|---|---|---|
| Children (2–11 years) | Higher doses per kg typically required; faster clearance of factor X in younger patients | 60 IU/kg |
| Adolescents (12–18 years) | Same dosing principles as adults; individualized based on weight and factor X levels | 60 IU/kg |
| Adults (18+ years) | Individualized by hematologist based on baseline factor X level, weight, and clinical scenario | 60 IU/kg |
Reconstitution and Administration
Before you can inject Coagadex, the powder must be dissolved (reconstituted) in the solvent provided with the product. Only use the solvent supplied in the package. The reconstitution volumes are as follows:
| Coagadex Strength | Solvent Volume |
|---|---|
| 250 IU | 2.5 mL |
| 500 IU | 5 mL |
Reconstitution is performed using the Mix2Vial needle-free transfer device included in each package. Ensure that the vials have reached room temperature before mixing. The reconstituted solution should be colorless, clear, or slightly opalescent (pearly). Do not use the solution if it is cloudy, contains particles, or forms a gel or clump. Once reconstituted, the solution must be used within one hour.
Step 1: Remove the caps from both the powder and solvent vials. Clean the stoppers with an alcohol swab. Open the Mix2Vial package but leave the device inside.
Step 2: Place the blue end of the transfer device onto the solvent vial and push down until it snaps into place. Remove the outer plastic casing.
Step 3: Invert the solvent vial and place the clear end of the device onto the powder vial. Push down until it snaps into place.
Step 4: The solvent will be drawn into the powder vial by vacuum. Gently swirl (do not shake) until the powder is fully dissolved, typically within 1 minute (maximum 5 minutes).
Step 5: Separate the empty solvent vial and blue adapter. Attach a syringe (not included) to the clear adapter, push air into the vial, then invert and draw the solution into the syringe.
Step 6: Inject intravenously following standard safety procedures. Do not use the product if the vacuum has been lost (solvent does not flow into powder vial).
Missed Dose
Do not take a double dose to make up for a forgotten dose. If you are on a prophylactic regimen and miss a scheduled dose, inject your normal dose as soon as you remember and then continue dosing according to your doctor's instructions. If you are uncertain about what to do, contact your healthcare provider for guidance.
Overdose
If you have used more Coagadex than your doctor has prescribed, there is a risk of developing a blood clot (thrombosis). If you think you may have used too much, stop the injection and contact your doctor, pharmacist, or nurse immediately. Symptoms of thrombosis may include leg pain or swelling, chest pain, shortness of breath, or sudden numbness or weakness on one side of the body.
Stopping Treatment
Always consult your doctor before deciding to stop your treatment with Coagadex. Abruptly discontinuing prophylactic treatment may increase your risk of bleeding episodes. Your hematologist will advise you on the safest approach to modifying or stopping your treatment regimen.
What Are the Side Effects of Coagadex?
Like all medicines, Coagadex can cause side effects, although not everybody gets them. The side effects observed in clinical trials and post-marketing surveillance are described below, organized by frequency. Understanding the potential side effects helps patients and caregivers recognize symptoms early and seek appropriate medical attention when needed.
Common Side Effects
- Pain or redness at the injection site
- Fatigue (tiredness)
- Back pain
Rare Side Effects
- Allergic reactions (hypersensitivity), which may include:
- Skin rash, including hives (urticaria)
- Tingling sensation
- Hot flushes
- Nausea and vomiting
- Headache
- Cough and wheezing
- Chest tightness
- Chills
- Rapid heartbeat (tachycardia)
- Dizziness and lethargy
- Restlessness
- Facial swelling
- Throat tightness
- Discomfort at the injection site
- Anaphylactic shock (in severe cases of hypersensitivity)
Inhibitor development: An additional risk associated with treatment is the development of inhibitory antibodies (inhibitors) against factor X. If inhibitors develop, the medication may become less effective, and your doctor will need to adjust your treatment plan. The frequency of inhibitor development in patients receiving Coagadex has not been precisely established due to the rarity of the condition, but your hematologist will perform regular monitoring.
Side effects in children and adolescents: The side effects observed in children and adolescents are expected to be the same as those reported in adults. The pediatric safety profile from clinical studies has been consistent with that of the adult population.
Contact your doctor or go to the nearest emergency department immediately if you experience signs of a severe allergic reaction such as difficulty breathing, severe skin rash or hives, swelling of the face or throat, rapid heartbeat, dizziness, or loss of consciousness. Also seek urgent medical advice if you develop symptoms of a blood clot, such as leg pain with swelling, chest pain, or sudden shortness of breath.
Reporting Side Effects
Reporting suspected side effects after the medicine has been authorized is important. It allows continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority. In the EU, reports can be submitted to the national competent authority, while in the US, adverse events can be reported to the FDA MedWatch program.
How Should You Store Coagadex?
Proper storage of Coagadex is essential to maintain the stability and effectiveness of the medication. The powder and solvent should be stored according to the following guidelines:
- Temperature: Store at or below 30°C (86°F). Do not freeze the product at any time, as freezing may damage the protein structure of factor X and render the product ineffective.
- Light protection: Keep the vial in the outer carton to protect from light exposure, which can degrade the active ingredient over time.
- Expiry date: Do not use Coagadex after the expiration date printed on the packaging. The expiration date refers to the last day of the stated month.
- After reconstitution: Once the powder has been dissolved in the solvent, the solution must be used within one hour. Do not store or refrigerate the reconstituted solution.
- Visual inspection: Do not use the product if you notice small particles in the reconstituted solution, if it appears cloudy, or if it forms a gel or clump.
Your treatment center will provide you with a special sharps container for disposing of any remaining solution, used syringes, needles, and empty packaging. Do not dispose of medicines through household waste or wastewater. These measures help to protect the environment and ensure safe disposal of biohazardous materials.
What Does Coagadex Contain?
Coagadex is a white to yellowish-white powder supplied together with solvent (water for injections) in separate vials. After reconstitution, the solution is colorless, clear, or slightly opalescent (pearly). Inspect the solution visually before injection and do not use it if it is cloudy or contains particles.
Active Ingredient
The active substance is human coagulation factor X, a plasma-derived glycoprotein purified from human donor plasma. Each vial contains approximately 250 IU or 500 IU of human coagulation factor X.
Inactive Ingredients (Excipients)
- Citric acid
- Disodium phosphate dihydrate
- Sodium chloride
- Sodium hydroxide (for pH adjustment)
- Sucrose
Solvent: Water for injections
Package Contents
| Package | Contents |
|---|---|
| 250 IU Pack | 1 vial of 250 IU powder, 1 vial of 2.5 mL water for injections, 1 Mix2Vial transfer device |
| 500 IU Pack | 1 vial of 500 IU powder, 1 vial of 5 mL water for injections, 1 Mix2Vial transfer device |
Not all pack sizes may be marketed in all countries. Coagadex is manufactured by PharmaKorell GmbH (Germany) and marketed by Kedrion S.p.A. (Italy).
Frequently Asked Questions About Coagadex
Coagadex is a plasma-derived human coagulation factor X concentrate used to treat and prevent bleeding episodes in patients with hereditary factor X deficiency. It can also be used to provide hemostatic coverage during surgical procedures. Factor X deficiency is a rare inherited bleeding disorder, and Coagadex is the first and only factor X-specific concentrate approved for this condition.
Coagadex is administered as an intravenous injection directly into a vein. The powder must first be reconstituted with the supplied solvent using the Mix2Vial needle-free transfer device. After proper training from a healthcare professional, patients or caregivers may administer Coagadex at home. The reconstituted solution must be used within one hour of preparation.
The most common side effects of Coagadex (occurring in up to 1 in 10 people) include injection site pain or redness, fatigue, and back pain. Rare allergic reactions (hypersensitivity) may occur, including skin rash, hives, tingling, hot flushes, nausea, headache, chest tightness, and rapid heartbeat. Seek immediate medical attention if you experience signs of a severe allergic reaction.
Yes, Coagadex can be used in children aged 2 years and older, as well as adolescents. Children under 12 years of age typically require higher doses per kilogram of body weight compared to adults and adolescents. Your child's hematologist will determine the appropriate dose based on their body weight, factor X levels, and clinical situation.
Coagadex is manufactured from human plasma and includes multiple viral inactivation and removal steps. While the risk of transmitting infections such as HIV, hepatitis B, and hepatitis C is considered extremely low due to donor screening and manufacturing processes, the risk cannot be entirely eliminated. Your doctor may recommend vaccination against hepatitis A and B if you receive plasma-derived factor concentrates regularly.
If your bleeding does not stop or continues longer than expected after a Coagadex injection, contact your healthcare provider immediately. This could indicate that you have developed inhibitory antibodies (inhibitors) against factor X, which can prevent the treatment from working properly. Your doctor will perform laboratory tests to check for inhibitors and determine an appropriate alternative treatment strategy.
References
All medical information in this article is based on peer-reviewed research, official prescribing information, and international medical guidelines. The following sources were used:
- 1 European Medicines Agency (EMA). Coagadex – Summary of Product Characteristics. Last updated 2024. Available from: EMA Coagadex EPAR
- 2 U.S. Food and Drug Administration (FDA). Coagadex – Prescribing Information. Approved October 2015, updated 2023. Available from: FDA Coagadex
- 3 Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
- 4 Menegatti M, Peyvandi F. Factor X deficiency. Seminars in Thrombosis and Hemostasis. 2009;35(4):407–415. doi:10.1055/s-0029-1225763
- 5 Austin SK, Kavakli K, Norton M, et al. Efficacy, safety, and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia. 2016;22(3):419–426. doi:10.1111/hae.12893
- 6 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Seminars in Thrombosis and Hemostasis. 2013;39(6):579–584. doi:10.1055/s-0033-1353394
- 7 World Health Organization (WHO). Model List of Essential Medicines, 23rd edition. Geneva: WHO; 2023.
- 8 International Society on Thrombosis and Haemostasis (ISTH). Guidelines on the diagnosis and management of rare coagulation disorders. 2023.
Editorial Team
This article was written by the iMedic Medical Editorial Team, specialists in hematology and clinical pharmacology. All content has been reviewed according to our strict editorial standards, following international guidelines from the EMA, FDA, WFH, and ISTH.
iMedic Medical Editorial Team – Licensed physicians specializing in hematology, coagulation disorders, and clinical pharmacology.
iMedic Medical Review Board – Independent panel of medical experts ensuring accuracy, completeness, and adherence to current evidence-based guidelines.
Evidence Level: All clinical claims in this article are supported by Level 1A evidence (systematic reviews, randomized controlled trials, and international clinical guidelines) or official product information (EMA SmPC, FDA prescribing information).
Conflict of Interest: The iMedic editorial team has no financial relationships with pharmaceutical companies. This content is independently produced with no commercial funding or sponsorship.
Last Reviewed: